Literature DB >> 32185502

Nonalcoholic Fatty Liver Disease.

Lingling Ding1, Yvonne Oligschlaeger1, Ronit Shiri-Sverdlov1, Tom Houben2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.
© 2020. The Author(s).

Entities:  

Keywords:  Atherosclerosis; Epidemiology; NAFLD; Pathogenesis; Treatment

Mesh:

Year:  2022        PMID: 32185502     DOI: 10.1007/164_2020_352

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  287 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

3.  NAFLD: The clinical and economic burden of NAFLD: time to turn the tide.

Authors:  Manal F Abdelmalek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-09       Impact factor: 46.802

4.  Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis.

Authors:  Lorena Airaghi; Mario Rango; Diletta Maira; Valentina Barbieri; Luca Valenti; Rosa Lombardi; Pietro Biondetti; Silvia Fargion; Anna Ludovica Fracanzani
Journal:  Atherosclerosis       Date:  2017-11-16       Impact factor: 5.162

Review 5.  Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.

Authors:  Agustín Albillos; Margaret Lario; Melchor Álvarez-Mon
Journal:  J Hepatol       Date:  2014-08-15       Impact factor: 25.083

6.  Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction.

Authors:  Zvi Ackerman; Mor Oron-Herman; Maria Grozovski; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela
Journal:  Hypertension       Date:  2005-04-11       Impact factor: 10.190

7.  Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Sang Bong Ahn; Kiseok Jang; Dae Won Jun; Byung Hoon Lee; Kye Jung Shin
Journal:  Dig Dis Sci       Date:  2014-08-08       Impact factor: 3.199

8.  Predictors of health-related quality of life in patients with chronic liver disease.

Authors:  A Afendy; J B Kallman; M Stepanova; Z Younoszai; R D Aquino; G Bianchi; G Marchesini; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2009-06-09       Impact factor: 8.171

9.  DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery.

Authors:  Markus Ahrens; Ole Ammerpohl; Witigo von Schönfels; Julia Kolarova; Susanne Bens; Timo Itzel; Andreas Teufel; Alexander Herrmann; Mario Brosch; Holger Hinrichsen; Wiebke Erhart; Jan Egberts; Bence Sipos; Stefan Schreiber; Robert Häsler; Felix Stickel; Thomas Becker; Michael Krawczak; Christoph Röcken; Reiner Siebert; Clemens Schafmayer; Jochen Hampe
Journal:  Cell Metab       Date:  2013-08-06       Impact factor: 27.287

10.  Extracellular ATP Activates the NLRP3 Inflammasome and Is an Early Danger Signal of Skin Allograft Rejection.

Authors:  Joaquín Amores-Iniesta; Maria Barberà-Cremades; Carlos M Martínez; José A Pons; Beatriz Revilla-Nuin; Laura Martínez-Alarcón; Francesco Di Virgilio; Pascual Parrilla; Alberto Baroja-Mazo; Pablo Pelegrín
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

View more
  3 in total

1.  Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis.

Authors:  Xiaofang Zhang; Yuchan Mou; Elif Aribas; Masoud Amiri; Jana Nano; Wichor M Bramer; Maryam Kavousi; Robert J de Knegt; Eralda Asllanaj; Mohsen Ghanbari
Journal:  Genes (Basel)       Date:  2022-05-27       Impact factor: 4.141

2.  Synergistic delivery of resveratrol and ultrasmall copper-based nanoparticles by aptamer-functionalized ultrasound nanobubbles for the treatment of nonalcoholic fatty liver disease.

Authors:  Xinmin Guo; Zhihui Huang; Jialin Chen; Kun He; Jianru Lin; Hui Zhang; Yanying Zeng
Journal:  Front Physiol       Date:  2022-09-09       Impact factor: 4.755

3.  Hemistepsin A inhibits T0901317-induced lipogenesis in the liver.

Authors:  Jae Kwang Kim; Il Je Cho; Eun Ok Kim; Dae Geon Lee; Dae Hwa Jung; Sung Hwan Ki; Sae Kwang Ku; Sang Chan Kim
Journal:  BMB Rep       Date:  2021-02       Impact factor: 4.778

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.